

Market Outlook

The Nifty 50 closed at 25,763, starting the week on a gap-down note but witnessing a rebound from the day's low. On the daily chart, the index took support near the 25,600 mark, which aligns with the 20-day EMA, indicating a potential reversal zone. On the derivatives front, fresh Put OI build-up at the 25,600 and 25,700 strikes suggests that holding above these levels could sustain the bullish bias within the on going consolidation phase. On the upside, the 26,000 level continues to act as a psychological hurdle.

Key Indices Update

INDEX	CLOSE	CHANGE (%)
NIFTY	25763.35	0.16
SENSEX	83978.49	0.05
BANKNIFTY	58101.45	0.56
INDIA VIX	12.66	4.22

FII's STATISTICS


FII's F&O Data

Sector	Buy/Sell	Change in OI
Index Futures	-1194.15	3.95%
Index Options	-5302.02	-1.00%
Stock Futures	-992.56	0.17%
Stock Options	-53.52	13.79%

FII's & DII's Cash Segment (Rs. In Crore)

Category	Amount	MTD	YTD
FII	-1883.78	-1884	-112104
DII	3516.36	3516	445966

FII's Activity in Index Future



Amt in Crores


NIFTY 50 HIGH DELIVERY STOCKS

SYMBOL	DELIVERABLE QTY	CHG IN DLY RATIO VS PREV DAY	% CHG IN TRD QTY OVER PREV DAY
ETERNAL	19416673	-9.14	-2.02
COALINDIA	10597994	13.19	8
HDFCBANK	9995580	-2.38	-28.48
ICICIBANK	6986020	-11.48	-30.49
NTPC	6494311	-2.25	-45.09
POWERGRID	5582900	-8.85	-14.97
TMPV	4506210	1.7	11.73
ITC	4411700	5.96	-58.95
AXISBANK	4211055	-6.56	49
INFY	3175928	-4.59	13.5


NIFTY

Nifty	25904.40
OI (In contracts)	241657
CHANGE IN OI (%)	-0.10
PRICE CHANGE (%)	0.00
IMPLICATION	NEUTRAL

NIFTY (CLOSE VS OI)



NIFTY OPTION CHAIN




Long Buildup

Symbol	Price	Price %	OI	OI %
POWERINDIA	17889	0.30	3562	41.90
UNOMINDA	1261.2	1.90	8080	14.30
DABUR	503.2	3.10	19494	12.80
COALINDIA	390.45	0.10	47051	12.20
PPLPHARMA	200.4	0.30	8855	10.90


BANKNIFTY

Banknifty	58429.00
OI (In contracts)	56093
CHANGE IN OI (%)	4.70
PRICE CHANGE (%)	0.40
IMPLICATION	LONG BUILDUP

BANKNIFTY (CLOSE VS OI)



BANKNIFTY OPTION CHAIN



Short Buildup

Symbol	Price	Price %	OI	OI %
PATANJALI	577	-4.80	42823	16.10
BLUESTARCO	1905.2	-2.10	4738	11.30
COLPAL	2203	-1.10	25852	6.80
KEI	4005	-0.90	6750	6.70
MARUTI	15716	-3.50	60399	6.30

Top 10 High PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
PETRONET	13779000	10234800	1.35
BHEL	40600875	32610375	1.25
ALKEM	135500	119625	1.13
CANBK	102168000	93663000	1.09
HINDALCO	13744500	12601400	1.09
IOC	55531125	51387375	1.08
UNOMINDA	1123650	1054900	1.07
JINDALSTEL	5026250	4841875	1.04
AUBANK	4302000	4213000	1.02
FEDERALBNK	40300000	39785000	1.01

Top 10 Low PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
GMRAIRPORT	34379775	109200600	0.31
NESTLEIND	1785000	4779500	0.37
PATANJALI	4826700	12663900	0.38
SHREECEM	40025	99100	0.4
YESBANK	157397100	396773800	0.4
HINDZINC	9254875	22331750	0.41
MARUTI	1332350	3281700	0.41
MAZDOCK	1526175	3736250	0.41
JSWENERGY	4704000	11160000	0.42
KEI	314825	723975	0.43

NIFTY 50 SUPPORT-RESISTANCE LEVELS

SYMBOL	R1	R2	PP	S1	S2
ADANIENT	2536	2580	2510	2466	2440
ADANIPORTS	1471	1481	1461	1450	1440
APOLLOHOSP	7805	7890	7747	7662	7604
ASIANPAINT	2540	2558	2527	2510	2497
AXISBANK	1250	1259	1244	1235	1230
BAJAJ-AUTO	9065	9219	8945	8791	8671
BAJAJFINSV	2129	2156	2114	2087	2072
BAJFINANCE	1068	1085	1058	1040	1030
BEL	436	443	423	416	403
BHARTIARTL	2079	2091	2072	2061	2053
CIPLA	1527	1546	1516	1497	1486
COALINDIA	394	399	391	387	384
DRREDDY	1203	1210	1198	1191	1187
EICHERMOT	7141	7230	7038	6949	6845
ETERNAL	328	336	323	315	311
GRASIM	2950	2996	2923	2877	2850
HCLTECH	1560	1570	1554	1543	1537
HDFCBANK	1007	1019	997	985	975
HDFCLIFE	748	759	742	730	724
HINDALCO	862	870	856	848	843
HINDUNILVR	2476	2489	2462	2449	2435
ICICIBANK	1366	1378	1359	1348	1341
INDIGO	5721	5785	5679	5615	5573
INFY	1490	1501	1484	1473	1467
ITC	428	434	423	418	413

SYMBOL	R1	R2	PP	S1	S2
JIOFIN	312	315	310	307	305
JSWSTEEL	1221	1230	1212	1204	1195
KOTAKBANK	2140	2164	2127	2103	2090
LT	4079	4104	4038	4013	3972
M&M	3537	3565	3522	3494	3479
MARUTI	16585	16883	16314	16016	15745
MAXHEALTH	1174	1193	1163	1144	1133
NESTLEIND	1289	1297	1283	1274	1269
NTPC	342	348	338	332	328
ONGC	259	261	257	254	252
POWERGRID	288	291	287	284	282
RELIANCE	1504	1512	1496	1488	1480
SBILIFE	1973	1987	1965	1951	1943
SBIN	952	961	943	934	926
SHRIRAMFIN	770	791	749	728	706
SUNPHARMA	1723	1746	1710	1687	1674
TATACONSUM	1186	1199	1175	1161	1150
TATASTEEL	185	186	184	183	182
TCS	3093	3111	3069	3051	3026
TECHM	1444	1454	1436	1426	1419
TITAN	3798	3826	3778	3750	3731
TMPV	418	424	414	408	404
TRENT	4760	4808	4732	4683	4655
ULTRACEMCO	12108	12205	12049	11952	11893
WIPRO	243	244	242	241	240

Research Team

Name	Email ID
<i>Ajit Mishra</i>	ajit.mishra@religare.com
<i>Abhijeet Banerjee</i>	abhijeet.banerjee@religare.com
<i>Gaurav Sharma</i>	gauravsharma2@religare.com
<i>Ashwani Harit</i>	ashwani.harit@religare.com
<i>Divya Parmar</i>	divya.parmar@religare.com
<i>Rajan Gupta</i>	rajan.gupta1@religare.com
<i>Vivek Chandra</i>	vivek.chandra@religare.com
<i>Himanshu Gupta</i>	himanshu.gupta1@religare.com
<i>Vishvajeet Singh</i>	vishvajeet.singh1@religare.com

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes:

..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results